DT-109

• Background :

  Glycine-containing peptide which has been demonstrated to ameliorate nonalcoholic fatty liver disease (NAFLD) . It improved body composition, and lowered circulating glucose, lipids, transaminases, proinflammatory cytokines and steatohepatitis in mice with established NASH.1 It dose-dependently attenuates NASH and fibrosis in mice as well as in nonhuman primates.2 It induced glutathione biosynthesis in mononuclear cells and demonstrated atheroprotective activity.3

• Conjugation :

  Unconjugated

• Buffer :

  White solid

• Storage Conditions :

  -20°C